December 21, 2016
FDA accepts Vernalis and Tris Pharma’s NDA for cough drug
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 21, 2016
Bayer and Leica Biosystems unite to fight cancer
Bayer has entered into an agreement with Leica Biosystems to collaborate on the development of companion diagnostic tests based on…
December 21, 2016
Premaitha buys Taiwanian bioinformatic company
Premaitha has announced the conditional acquisition of the entire issued share capital of Yourgene.
December 20, 2016
Allergan eats LifeCell for $2,9 billion
Allergan has acquired the regenerative medicine company LifeCell for $2.9 billion in cash.
December 20, 2016
BMS gets exclusive rights to study PsiOxus’s cancer drug
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…
December 20, 2016
Japan to step up drug price reviews in bid to curbhealthcare costs
Japan said on Tuesday it will step up the pace and expand the scope of drug price reviews, one of the most aggressive measures it is taking to rein in ballooning healthcare costs for a rapidly ageing nation.
December 20, 2016
Pharnext enrolls patients for Charcot-Marie-Tooth disease study in Europe, US, and Canada.
A French biopharmaceutical company Pharnext set to produce treatments to tackle neuropathy diseases, has completed patient enrollment for its international…
December 20, 2016
Novartis buys private US-based pharma company, exapnds its ophtalmology pipeline
Novarits is expanding its ophthalmology pipeline as it secured the ownership of a US-based private company focused on treating long-sightedness.
December 20, 2016
Not your mother’s Pap smear
Confused about when to get your next Pap test? Anxious because your doctor said you don’t need another Pap for five years? Well, you are not alone.
December 20, 2016
GSKs two-drug HIV treatment regimen could become one tablet
Two phase III studies of two-drug HIV treatment regimen conducted by GSK’s HIV specialist ViiV Healthcare, Pfizer and Shinogi Limited,…